Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) Return on Sales (2016 - 2025)

IGC Pharma (IGC) has disclosed Return on Sales for 16 consecutive years, with 9.53% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Sales fell 537.0% to 9.53% in Q3 2025 year-over-year; TTM through Sep 2025 was 5.83%, a 480.0% increase, with the full-year FY2025 number at 5.6%, up 406.0% from a year prior.
  • Return on Sales was 9.53% for Q3 2025 at IGC Pharma, down from 4.88% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 3.63% in Q1 2025 to a low of 77.57% in Q3 2021.
  • A 5-year average of 18.47% and a median of 9.78% in 2024 define the central range for Return on Sales.
  • Biggest YoY gain for Return on Sales was 7235bps in 2021; the steepest drop was -6432bps in 2021.
  • IGC Pharma's Return on Sales stood at 16.77% in 2021, then skyrocketed by 60bps to 6.77% in 2022, then crashed by -304bps to 27.4% in 2023, then skyrocketed by 74bps to 7.12% in 2024, then crashed by -34bps to 9.53% in 2025.
  • Per Business Quant, the three most recent readings for IGC's Return on Sales are 9.53% (Q3 2025), 4.88% (Q2 2025), and 3.63% (Q1 2025).